Genmab A/S (OTCMKTS:GNMSF - Get Free Report) was the target of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 76,300 shares, a decrease of 10.1% from the October 15th total of 84,900 shares. Based on an average daily trading volume, of 16,400 shares, the short-interest ratio is presently 4.7 days.

Shares of Genmab A/S stock traded down $7.79 on Monday, hitting $212.71. 1,000 shares of the company were exchanged, compared to its average volume of 2,488. The stock has a market capitalization of $13.90 billion, a price-to-earnings ratio of 20.45 and a beta of 1.07. Genmab A/S has a 1-year low of $202.30 and a 1-year high of $334.33. The company has a 50-day moving average price of $236.51 and a 200 day moving average price of $258.78.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.